FR941003-0-00065 FR941003-0-00013 Description of Respondents: Businesses. Estimated Annual Reporting and Recordkeeping Burden 1Section 1No. of respondents 1No. of responses per respondent 1Total annual responses 1Hours per response 1Total hours 314.50(i) 8 1 8 2 16 314.50(j) 50 1 50 2 100 314.52 30 1 30 8 240 314.53 200 1 200 1 200 314.94(a)(12) 215 1 215 2 430 314.95 30 1 30 16 480 314.107 10 1 10 10 10 n,n,n,n,n,s Total 1,476 There were no comments received on the Paperwork Reduction Act clearance submission or on the burden estimates. The agency has, however, revised the estimate for ANDA's under §314.94 based on its latest figures for the number of ANDA's received. VII. References The following references have been placed on display in the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857, and may be seen by interested persons between 9 a.m. and 4 p.m., Monday through Friday. 1. Letter dated September 28, 1992, from Jane E. Henney, Deputy Commissioner for Operations, to Alan H. Kaplan and Richard S. Morey, Kleinfeld, Kaplan and Becker (FDA Docket No. 90P&hyph;0455). 2. Letter dated December 8, 1987, from John M. Taylor, Associate Commissioner for Regulatory Affairs, to Bruce J. Brennan, Senior Vice President and General Counsel (FDA Docket No. 86P&hyph;0235/CP). List of Subjects in 21 CFR Part 314 Administrative practice and procedure, Confidential business information, Drugs, Reporting and recordkeeping requirements. Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 314 is amended as follows: PART 314_APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG OR AN ANTIBIOTIC DRUG 1. The authority citation for 21 CFR part 314 continues to read as follows: Authority: Secs. 201, 301, 501, 502, 503, 505, 506, 507, 701, 704, 721 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 331, 351, 352, 353, 355, 356, 357, 371, 374, 379e). 2. Section 314.50 is amended by redesignating existing paragraph (h) as paragraph (k) and by adding new paragraphs (h), (i), and (j) to read as follows: §314.50 Content and format of an application. * * * * * (h) Patent information. The application is required to contain the patent information described under §314.53. (i) Patent certification _(1) Contents. A 505(b)(2) application is required to contain the following: (i) Patents claiming drug, drug product, or method of use. (A) Except as provided in paragraph (i)(2) of this section, a certification with respect to each patent issued by the United States Patent and Trademark Office that, in the opinion of the applicant and to the best of its knowledge, claims a drug (the drug product or drug substance that is a component of the drug product) on which investigations that are relied upon by the applicant for approval of its application were conducted or that claims an approved use for such drug and for which information is required to be filed under section 505 (b) and (c) of the act and §314.53. For each such patent, the applicant shall provide the patent number and certify, in its opinion and to the best of its knowledge, one of the following circumstances: ( 1 ) That the patent information has not been submitted to FDA. The applicant shall entitle such a certification ``Paragraph I Certification''; ( 2 ) That the patent has expired. The applicant shall entitle such a certification ``Paragraph II Certification''; ( 3 ) The date on which the patent will expire. The applicant shall entitle such a certification ``Paragraph III Certification''; or ( 4 ) That the patent is invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of the drug product for which the application is submitted. The applicant shall entitle such a certification ``Paragraph IV Certification''. This certification shall be submitted in the following form: I, ( name of applicant ), certify that Patent No. XXXXXX ( is invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of ) ( name of proposed drug product ) for which this application is submitted. The certification shall be accompanied by a statement that the applicant will comply with the requirements under §314.52(a) with respect to providing a notice to each owner of the patent or their representatives and to the holder of the approved application for the drug product which is claimed by the patent or a use of which is claimed by the patent and with the requirements under §314.52(c) with respect to the content of the notice. (B) If the drug on which investigations that are relied upon by the applicant were conducted is itself a licensed generic drug of a patented drug first approved under section 505(b) of the act, the appropriate patent certification under this section with respect to each patent that claims the first-approved patented drug or that claims an approved use for such a drug. (ii) No relevant patents. If, in the opinion of the applicant and to the best of its knowledge, there are no patents described in paragraph (i)(1)(i) of this section, a certification in the following form: In the opinion and to the best knowledge of ( name of applicant ), there are no patents that claim the drug or drugs on which investigations that are relied upon in this application were conducted or that claim a use of such drug or drugs.
